Annals of the New York Academy of Sciences · 1991 · 27 citations · 6 references
MedicinePharmacologyPsychiatryDementiaNeuropharmacologyPsychopharmacologyAntidepressant PharmacotherapyAntidepressant TherapyCognitive ImpairmentDementia PharmacotherapyDementia TreatmentSerotonergic PharmacologyAntidepressant MedicationsAntidepressant Use In DementiaPharmacological Treatment Of DementiaPostmortem Brain ExaminationSelective Serotonin Reuptake Inhibitor UseVascular Dementia Pharmacotherapy
In patients with Alzheimer's disease and vascular dementia, there are symptoms not only of cognitive impairment but also of emotional disturbance. Postmortem human brain studies have shown a disturbed metabolism of serotonin and overactivity of neuroendocrine-controlling factors in the hypothalamus. Treatment with a selective 5-HT reuptake blocker, citalopram, causes a significant reduction in postdexamethasone cortisol levels. Citalopram in patients with dementia disorders produces no improvement in psychomotor and cognitive behavior, but symptoms of emotional disturbance are reduced. Citalopram does not have a pure antidepressant effect; rather, the drug is considered an emotional stabilizer.
6
Transmitter deficits in Alzheimer's disease
John Hardy, Rolf Adolfsson, Irina Alafuzoff et al. · Neurochemistry International · 1985 · 330 citations
A new rating scale for dementia syndromes
C. G. Gottfries, Görel Bråne, Bo Gullberg et al. · Archives of Gerontology and Geriatrics · 1982 · 283 citations
Medicine, Neurology, Psychiatry +14
Hypothalamic monoamines and neuropeptides in dementia
Anders Wallin, Arvid Carlsson, Rolf Ekman et al. · European Neuropsychopharmacology · 1991 · 26 citations
Medicine, Neurobiology, Neuroscience +12